Supercritical CO₂ solutions for industrial applications
Vision & Mission
Biotech One is a deep tech technology provider delivering clean and competitive supercritical CO₂–based solutions to address critical industrial challenges in nanoparticle encapsulation, extraction, and sterilization processing.
Our solutions are designed with a strong focus on process robustness, scalability, and industrial readiness, enabling reliable deployment from R&D to full-scale manufacturing.
We operate as an industrial technology enabler, designing and delivering deployable process platforms that allow manufacturers to industrialize supercritical CO₂ technologies within their own production environments.
Market & Applications
Biotech One’s supercritical CO₂ technologies are designed for industrial markets with strong technical and regulatory constraints, and are applied across the following segments:
-
Pharmaceuticals & biotechnology – encapsulation, formulation, clean processing
- Nutraceuticals, Food products, & cosmetics – extraction, fractionation, solvent-free processing
- Medical devices & healthcare products – sterilization and low-temperature processing
- Energy, renewables & bio-based materials – bio-oils, waste valorization, advanced materials
Across these segments, our platforms enable:
- Extraction / fractionation of sensitive compounds
- Encapsulation and nanoparticle formulation
- Sterilization and cleaning processing
Products & services
Integrated solutions for encapsulation, extraction and sterilization using sc CO2 technology
Research & Innovation
R&D studies and proof-of-concept (PoC)
Feasibility studies and experimental validation
Process optimization
Scale-up
Co-development
Joint development programs to adapt supercritical CO₂ technologies to specific applications and scale-up requirements.
Development & production
Equipment
Design and sale of industrial systems, including the EncapX® encapsulation system for continuous production of lipid nanoparticles and nanoliposomes.
Licensing & support
Technology licensing, process transfer, and technical support to enable integration into industrial environments.
Limited pilot and demonstration batches of extracted or encapsulated ingredients
Ingredients may be produced to support PoC, process optimization, and industrial validation
R&D & Technology platforms
R&D
Biotech One combines applied R&D, academic collaboration, and industrial engineering to support the transition from proof-of-concept to industrial deployment.
The company operates within a strong scientific and institutional ecosystem and is actively involved in European R&D programs supporting the industrialization of clean and sustainable processing technologies.
Discover more
Our technology platforms
- Encap-X® – Continuous encapsulation system for lipid nanoparticles and nanoliposomes
- Extract-X® – Clean extraction and fractionation platform
- Sterili-X® – CO₂-based sterilization and decontamination processes
All platforms are conceived as industrial tools, designed for robustness, scalability, and compatibility with regulated environments.
Key milestones & company history
Business & Funding
Research & Technology
Creation of Biotech One – Initial capital €445k
Award of the BPI “French Tech Grant” (€25k)
supporting R&D on supercritical CO₂ encapsulation processes
First commercial contracts in chemistry and cosmetics industries
R&D to develop patents, proprietary know-how, and industrial processes.
Technology validation through commercial collaborations with major industrial groups
Patent Extraction / Fractionation
Acquisition of an exclusive exploitation license for patents covering continuous extraction from algae without any drying step.
First commercial order for an EncapX automated system
EncapX patent - validation
Continuous millifluidic nanoliposome encapsulation process and equipment
FUNDRAISING
Entry of RSI (Région Sud Investissement) and CAAP Crédit Agricole into the company’s capital
Laureate HORIZON EUROPE Grant (Alliance)
(48 months – total project €8.75M – Biotech One share €445k)
Commercial scale-up and industrial deployment
R&D consolidation and full-scale validation within EU projects
Team
Fabien BALME
CTO/CEO. Master Degree in engineering. Over 35 years of experience as senior executive (Siemens) and serial entrepreneur with a healthcare exit.
Dr. Elissandro KLEIN
R&D Project Manager
Ph.D. in Chemical Engineering. Expert in supercritical fluid technologies. Leads R&D initiatives and supports client-facing innovation projects.
Scientific & Advisory Board
Management & R&D Core Team
Dr Omar SALMAN
Pharma, Ph.D. in Chemical Engineering. Awarded for his role in developing key components of the Pfizer-BioNTech COVID-19 vaccine.
Thierry Bourdillon
Représentant de CAAP Création (Crédit Agricole Alpes Provence). Responsable de participations chez CAAP Création
https://www.capital-innovation.ca-alpesprovence.fr/investisseur/
Benjamin BESSAC
Représentant de RSI - Région Sud Investissement . Chargé d'investissements
Pr. Elisabeth BADENS
Editor-in-Chief of the Journal of Supercritical Fluids. Chemical Engineer and Full Professor at Aix Marseille University. TEDx speaker.